Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00219999 · ClinicalTrials.gov registry record

Hepatitis C Virus and the Humoral Immune System

A clinical trial, sponsored by Rockefeller University.

Completed
Registry status
161
Enrollment target

NCT00219999 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 161 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00219999 has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
161 participants
Enrollment target

Study Summary

The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2001-09
Est. Completion 2013-05

Sponsor

Rockefeller University

117 total trials

What the Registry Record Tells You About NCT00219999

The ClinicalTrials.gov registry entry for NCT00219999 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00219999 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00219999 about?

NCT00219999 is a clinical study titled "Hepatitis C Virus and the Humoral Immune System". The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.

What is the current status of trial NCT00219999?

This trial is currently completed. The enrollment target is 161 participants. The study started on 2001-09. Estimated completion is 2013-05.

Who is sponsoring clinical trial NCT00219999?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.